These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68. The genetic influences on oxycodone response characteristics in human experimental pain. Olesen AE; Sato H; Nielsen LM; Staahl C; Droney J; Gretton S; Branford R; Drewes AM; Arendt-Nielsen L; Riley J; Ross J Fundam Clin Pharmacol; 2015 Aug; 29(4):417-25. PubMed ID: 26042474 [TBL] [Abstract][Full Text] [Related]
69. Personalized therapy in pain management: where do we stand? Stamer UM; Zhang L; Stüber F Pharmacogenomics; 2010 Jun; 11(6):843-64. PubMed ID: 20504256 [TBL] [Abstract][Full Text] [Related]
70. Using pharmacogenetics to structure individual pain management protocols in total knee arthroplasty. Hamilton WG; Gargiulo JM; Parks NL Bone Joint J; 2020 Jun; 102-B(6_Supple_A):73-78. PubMed ID: 32475277 [TBL] [Abstract][Full Text] [Related]
71. Cancer pain. Mercadante S Curr Opin Support Palliat Care; 2013 Jun; 7(2):139-43. PubMed ID: 23572159 [TBL] [Abstract][Full Text] [Related]
72. Genetics and genomics in postoperative pain and analgesia. Palada V; Kaunisto MA; Kalso E Curr Opin Anaesthesiol; 2018 Oct; 31(5):569-574. PubMed ID: 29994939 [TBL] [Abstract][Full Text] [Related]
73. Pharmacogenetics of Postoperative Pain Management: A Review. Aroke EN; Kittelsrud JM AANA J; 2020 Jun; 88(3):229-236. PubMed ID: 32442101 [TBL] [Abstract][Full Text] [Related]
74. [Prescription of antidepressants in the treatment of pain: role of pharmacogenetics]. Rodieux F; Piguet V; Berney P; Desmeules J; Besson M Rev Med Suisse; 2015 Jun; 11(480):1374-9. PubMed ID: 26267942 [TBL] [Abstract][Full Text] [Related]
75. Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness. Linares OA; Daly D; Linares AD; Stefanovski D; Boston RC Pain Med; 2014 May; 15(5):791-806. PubMed ID: 24517173 [TBL] [Abstract][Full Text] [Related]
76. OPRM1 Methylation Contributes to Opioid Tolerance in Cancer Patients. Viet CT; Dang D; Aouizerat BE; Miaskowski C; Ye Y; Viet DT; Ono K; Schmidt BL J Pain; 2017 Sep; 18(9):1046-1059. PubMed ID: 28456745 [TBL] [Abstract][Full Text] [Related]
77. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Lötsch J; Geisslinger G Trends Mol Med; 2005 Feb; 11(2):82-9. PubMed ID: 15694871 [TBL] [Abstract][Full Text] [Related]
78. Opioid-related deaths and previous care for drug use and pain relief in Sweden. Fugelstad A; Thiblin I; Johansson LA; Ågren G; Sidorchuk A Drug Alcohol Depend; 2019 Aug; 201():253-259. PubMed ID: 31260826 [TBL] [Abstract][Full Text] [Related]
79. Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. Gong XD; Wang JY; Liu F; Yuan HH; Zhang WY; Guo YH; Jiang B Asian Pac J Cancer Prev; 2013; 14(5):2937-43. PubMed ID: 23803057 [TBL] [Abstract][Full Text] [Related]
80. How individual sensitivity to opiates can be predicted by gene analyses. Ikeda K; Ide S; Han W; Hayashida M; Uhl GR; Sora I Trends Pharmacol Sci; 2005 Jun; 26(6):311-7. PubMed ID: 15925706 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]